Article Text

Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Management of a pregnant woman with common variable immunodeficiency and previous reactions to intravenous IgG administration
  1. Maria Giovanna Danieli1,
  2. Romina Moretti1,
  3. Lucia Pettinari2,
  4. Simona Gambini1
  1. 1Department of Scienze Cliniche e Molecolari, Clinica Medica, Torrette di Ancona, Italy
  2. 2Department of Medicina Interna, Medicina Interna, Loreto, Italy
  1. Correspondence to Maria Giovanna Danieli, m.g.danieli{at}


Common variable immunodeficiency is the most common symptomatic primary immunodeficiency in adulthood. Pregnant women with common variable immunodeficiency have different needs from other patients with the same disease. Because of immature state of the fetal and neonatal immune system, transplacental transfer of immunoglobulin G (IgG) has a relevant role in protecting the infant. We here report on a high-risk pregnant woman with common variable immunodeficiency with adverse reactions to intravenous immunoglobulin that was successfully rescued with a new Ig human intravenous, 10% liquid preparation. The treatment was tailored to the health status and characteristics of the patient. The new product was safe and well tolerated. The mother did not report any infections during pregnancy and the baby had a healthy course with ‘protective’ serum IgG levels. Our case is a further demonstration that intravenous immunoglobulin tolerability in patients with immunodeficiency could be linked to a product's characteristics.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.